Hanik Badriyah Hidayati, - and Evi Octavia, - and Cempaka Thursina Srisetyaningrum, - (2021) Antiviral therapy for COVID-2019. Anaesth, Pain & Intensive Care, 25 (3). pp. 387-392. ISSN 1607-8322

	Text (Peer Review) C-3 Peer Review.pdf Download (1MB)
	Text (Similarity) C-3 Turnitin.pdf Download (1MB)
	Text (Artikel) C-3 Artikel.pdf Download (4MB)
	Text (Bukti Korespondensi) C-3 Bukti Koresponding.pdf Download (3MB)

Abstract

The whole world is experiencing a global pandemic caused by Coronavirus disease 2019. As the pandemic progresses, there has been much research on antiviral drugs, such as hydroxychloroquin, chloroquine, remdesivir, lopinavir-ritonavir, favipiravir, oseltamivir, and umifenovir. Specific antiviral drugs proven to be effective against SARS-CoV-2 have not been found and approved for the medication of COVID-19. Currently, case detection, infection control, monitoring, prevention, and supportive care are the means focused on the treatment of COVID-19. A large scale research is currently underway to analyze safety and efficacy of antiviral drugs, while trials of the SAR-CoV-2 vaccine are rapidly expanding. This mini review briefly introduces the current antiviral therapy for COVID-19.

Item Type:	Article
Uncontrolled Keywords:	Antiviral therapy, Drugs, COVID-19
Subjects:	R Medicine > R Medicine (General) R Medicine > RC Internal medicine
Divisions:	01. Fakultas Kedokteran > Neurologi (Spesialis)
Creators:	Creators NIM Hanik Badriyah Hidayati, - NIDN0024097808 Evi Octavia, - UNSPECIFIED Cempaka Thursina Srisetyaningrum, - UNSPECIFIED
Depositing User:	arys fk
Date Deposited:	22 Aug 2022 04:42
Last Modified:	22 Aug 2022 04:42
URI:	http://repository.unair.ac.id/id/eprint/117645
Sosial Share:

Actions (login required)

View Item